Beyond the Dose-Limiting Toxicity Period: Dermatologic Adverse Events of Patients on Phase 1 Trials of the Cancer Therapeutics Evaluation Program

BACKGROUND: Dermatologic adverse events (AEs) can be key determinants of overall drug tolerability and of the maximum tolerated and recommended phase 2 doses in phase 1 trials. The authors present the largest dedicated analysis of dermatologic AEs on phase 1 trials to date. METHODS: Data from a pros...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Drilon, Alexander, Eaton, Anne A., Schindler, Katja, Gounder, Mrinal M., Spriggs, David R., Harris, Pamela, Ivy, S. Percy, Iasonos, Alexia, Lacouture, Mario E., Hyman, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5479632/
https://ncbi.nlm.nih.gov/pubmed/26916138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29918
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados